Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2009 Nov 10;77(4):1120–1127. doi: 10.1016/j.ijrobp.2009.06.067

Table 2.

All adverse events reported as definitely, probably, or possibly related to treatment (n = 52)

Grade

1 2 3
Blood/bone marrow 2 0 0
Cardiovascular (general) 1 0 0
Constitutional symptoms 13 1 0
Dermatology/skin 19 18 2
Endocrine 3 0 0
Gastrointestinal 2 0 0
Lymphatics 6 0 0
Musculoskeletal/soft tissue 5 7 1
Pain 9 7 0
Pulmonary 1 1 0
Sexual/reproductive function 4 5 0
Worst nonhematologic 17 (33%) 24 (46%) 2 (4%)
Worst overall 17 (33%) 24 (46%) 2 (4%)